349 related articles for article (PubMed ID: 7557656)
1. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
Carr ME; Carr SL; Merten SR
Haemostasis; 1995; 25(4):172-81. PubMed ID: 7557656
[TBL] [Abstract][Full Text] [Related]
2. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
3. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots.
Carr ME; Powers PL; Jones MR
Thromb Haemost; 1991 Nov; 66(5):565-8. PubMed ID: 1803621
[TBL] [Abstract][Full Text] [Related]
4. Effects of poloxamer 407 on the assembly, structure and dissolution of fibrin clots.
Carr ME; Carr SL; High AA
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):109-13. PubMed ID: 8735798
[TBL] [Abstract][Full Text] [Related]
5. [Effects of ionic and nonionic contrast media on the blood coagulation system, the fibrinolytic system and platelets].
Himi K; Himi S; Takemoto A; Kamata R
Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Sep; 51(9):1037-44. PubMed ID: 1945784
[TBL] [Abstract][Full Text] [Related]
6. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
7. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.
Carr ME; Dent RM; Carr SL
J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939
[TBL] [Abstract][Full Text] [Related]
8. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.
Carr ME; Zekert SL
Am J Physiol; 1994 Mar; 266(3 Pt 2):H1195-201. PubMed ID: 8160823
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
10. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
[TBL] [Abstract][Full Text] [Related]
11. Contrast, coagulation, and fibrinolysis.
Dawson P; Hewitt P; Mackie IJ; Machin SJ; Amin S; Bradshaw A
Invest Radiol; 1986 Mar; 21(3):248-52. PubMed ID: 3957598
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Braaten JV; Jerome WG; Hantgan RR
Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066
[TBL] [Abstract][Full Text] [Related]
13. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
Dehmer GJ; Gresalfi N; Daly D; Oberhardt B; Tate DA
J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
[TBL] [Abstract][Full Text] [Related]
14. Effect of various contrast media on coagulation, fibrinolysis, and platelet function. An in vitro and in vivo study.
Stormorken H; Skalpe IO; Testart MC
Invest Radiol; 1986 Apr; 21(4):348-54. PubMed ID: 3700048
[TBL] [Abstract][Full Text] [Related]
15. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
16. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
17. Effect of nonionic and ionic contrast media on fibrinolysis in patients undergoing angiography.
Giedrojć J; Radziwon P; Krupiński K; Kiełpińska K; Galar M; Bielawiec M
Pol J Pharmacol; 1996; 48(3):323-6. PubMed ID: 9112670
[TBL] [Abstract][Full Text] [Related]
18. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
19. Effect of iopentol on coagulation and platelet function in vitro and in vivo.
Stormorken H; Testart MC; Braekke G; Sveen K; Jakobsen JA; Grande T; Andrew E
Acta Radiol Suppl; 1987; 370():93-6. PubMed ID: 2980322
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell aggregation versus blood clot formation in ionic and nonionic contrast media.
Kimball JP; Sansone VJ; Diters LA; Wissel PS
Invest Radiol; 1988 Nov; 23 Suppl 2():S334-9. PubMed ID: 3198376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
